文献速递类风湿关节炎

仅因患者总体评估升高而未达Boolean缓解的RA患者细胞因子/趋化因子谱

Cytokine/chemokine profiles in rheumatoid arthritis patients who failed Boolean remission solely due to elevated patient global assessment.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

这项前瞻性队列研究分析了200例接受生物/靶向合成改善病情抗风湿药的RA患者,按12个月Boolean缓解状态分为完全缓解组(n=68)、仅PGA升高的近缓解组(n=50)和未缓解组(n=82),检测41种细胞因子/趋化因子及自身抗体。近缓解组基线IL-17和IL-10显著升高,12个月时持续IL-1β升高(P=0.007)且细胞因子网络密度维持高位,提示其症状具有炎症基础。

要点

  • 仅PGA升高的近缓解RA患者12个月时持续存在IL-1β升高。
  • 近缓解组基线IL-17和IL-10水平显著高于其他组。
  • 近缓解组12个月细胞因子网络密度未降低,与未缓解组相似。

核心结论

  • 仅因PGA升高未达Boolean缓解的RA患者表现为以持续IL-1β升高和细胞因子网络密度维持为特征的独特炎症表型。
  • 这些患者报告的症状具有炎症基础而非纯非炎症性,支持追求严格Boolean缓解的重要性。

研究设计与样本

  • 前瞻性队列研究纳入200例接受生物/靶向合成改善病情抗风湿药的RA患者。
  • 按12个月Boolean缓解状态分为完全缓解组(Group 0,n=68)、仅PGA升高的近缓解组(Group 1,n=50)和未缓解组(Group 2,n=82)。
  • 检测41种细胞因子/趋化因子及自身抗体以刻画炎症谱。

主要发现

  • 基线时Group 1的IL-17和IL-10水平显著高于其他组。
  • 12个月时Group 1持续IL-1β升高,而Group 0和Group 2该细胞因子不可测(P=0.007)。
  • 12个月时Group 1的IL-1α、IL-2、IL-4和TGF-α水平也较高。
  • 网络分析显示Group 0网络密度显著降低,而Group 1和Group 2在12个月时维持高连接性。

关键数值与推荐

  • 原版Boolean缓解要求压痛关节数≤1、肿胀关节数≤1、C反应蛋白≤1 mg/dl、患者总体评估(PGA)≤1。
  • 约30%患者满足客观标准但仅因PGA升高未达缓解,称为「近缓解」。

临床怎么用

  • 对仅PGA升高未达Boolean缓解的RA患者,应认识到其症状可能有炎症基础,而非单纯非炎症因素。
  • 支持将严格Boolean缓解作为治疗目标,并考虑针对残留炎症的靶向治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rheumatoid arthritis (RA) patients achieving original Boolean remission require a tender joint count ≤1, swollen joint count ≤1, C-reactive protein ≤1 mg/dl, and a patient global assessment (PGA) ≤1. Approximately 30% of patients meet the objective criteria but fail remission solely due to elevated PGA, termed 'near-remission'. The underlying mechanisms remain unclear, with debate whether persistent symptoms reflect residual inflammation or non-inflammatory factors. METHODS: This prospective cohort study analysed 200 RA patients receiving biologic/targeted synthetic disease-modifying antirheumatic drugs. Patients were stratified according to 12-month Boolean remission status as follows: complete remission (Group 0, n = 68), near-remission with elevated PGA only (Group 1, n = 50), and non-remission (Group 2, n = 82). We measured 41 cytokines/chemokines and auto-antibodies to characterize inflammatory profiles. RESULTS: At baseline, Group 1 exhibited significantly elevated IL-17 and IL-10 levels compared with the other groups. At 12 months, Group 1 showed persistent IL-1β elevation, whereas Groups 0 and 2 had undetectable levels of this cytokine (P = 0.007). Group 1 also showed higher IL-1α, IL-2, IL-4 and TGF-α levels at 12 months. Network analysis revealed that Group 0 achieved substantial network density reduction, whereas Groups 1 and 2 maintained high connectivity at 12 months. CONCLUSION: RA patients with near-remission exhibited a distinct inflammatory phenotype characterized by persistent IL-1β elevation and maintained cytokine network density. These findings suggest that patient-reported symptoms in these patients have an inflammatory basis rather than a purely non-inflammatory basis, supporting the importance of achieving stringent Boolean remission and highlighting the need for targeted therapeutic approaches. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry; http://www.umin.ac.jp/ctr/; #UMIN000012524.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Fukui S, Michitsuji T, Endo Y, et al. Cytokine/chemokine profiles in rheumatoid arthritis patients who failed Boolean remission solely due to elevated patient global assessment. Rheumatology (Oxford). 2026. PMID: 41548226. doi:10.1093/rheumatology/keag020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。